AstraZeneca PLC or Xencor, Inc.: Who Manages SG&A Costs Better?

AstraZeneca vs. Xencor: A Decade of SG&A Management

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, AstraZeneca PLC and Xencor, Inc. have demonstrated contrasting approaches. AstraZeneca, a global leader, averaged SG&A expenses of approximately $13.2 billion annually, peaking in 2022 with a 44% increase from 2014. In contrast, Xencor, a smaller biotech firm, maintained a leaner structure, with expenses growing from $7.5 million in 2014 to $53.4 million in 2023, marking a significant 615% rise. Despite the disparity in scale, Xencor's growth trajectory highlights its strategic expansion efforts. This analysis underscores the diverse strategies in SG&A management, reflecting each company's operational priorities and market positioning. As the industry evolves, these insights offer a glimpse into the financial stewardship shaping the future of pharmaceuticals.